301 related articles for article (PubMed ID: 14964344)
1. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens.
Callegan MC; Ramirez R; Kane ST; Cochran DC; Jensen H
Adv Ther; 2003; 20(5):246-52. PubMed ID: 14964344
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Oliveira AD; D'Azevedo PA; Francisco W
Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
[TBL] [Abstract][Full Text] [Related]
3. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
[TBL] [Abstract][Full Text] [Related]
4. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison.
Duggirala A; Joseph J; Sharma S; Nutheti R; Garg P; Das T
Indian J Ophthalmol; 2007; 55(1):15-9. PubMed ID: 17189881
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of bacterial keratitis isolates to fourth-generation fluoroquinolones.
Chawla B; Agarwal P; Tandon R; Titiyal JS; Sharma N; Agarwal T; Navak N; Satpathy G
Eur J Ophthalmol; 2010; 20(2):300-5. PubMed ID: 19924668
[TBL] [Abstract][Full Text] [Related]
6. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
Harper T; Miller D; Flynn HW
Ophthalmology; 2007 May; 114(5):871-5. PubMed ID: 17383732
[TBL] [Abstract][Full Text] [Related]
7. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
Scoper SV
Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
[TBL] [Abstract][Full Text] [Related]
8. Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Reddy AK; Garg P; Alam MR; Gopinathan U; Sharma S; Krishnaiah S
Eye (Lond); 2010 Jan; 24(1):170-4. PubMed ID: 19229279
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
Epstein SP; Bottone EJ; Asbell PA
Eye Contact Lens; 2006 Sep; 32(5):240-4. PubMed ID: 16974157
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Blondeau JM; Laskowski R; Bjarnason J; Stewart C
Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
[TBL] [Abstract][Full Text] [Related]
11. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment.
Abshire R; Cockrum P; Crider J; Schlech B
Clin Ther; 2004 Feb; 26(2):191-6. PubMed ID: 15038942
[TBL] [Abstract][Full Text] [Related]
12. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
[TBL] [Abstract][Full Text] [Related]
13. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Hesje CK; Borsos SD; Blondeau JM
J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
[TBL] [Abstract][Full Text] [Related]
14. [In vitro antibiotic susceptibility to fluoroquinolones].
Wong CA; Galvis V; Tello A; Villareal D; Rey JJ
Arch Soc Esp Oftalmol; 2012 Mar; 87(3):72-8. PubMed ID: 22423655
[TBL] [Abstract][Full Text] [Related]
15. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin.
Yamada M; Hatou S; Yoshida J
Eye Contact Lens; 2008 Mar; 34(2):109-12. PubMed ID: 18327047
[TBL] [Abstract][Full Text] [Related]
17. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Proksch JW; Ward KW
J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
[TBL] [Abstract][Full Text] [Related]
18. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin.
Deramo VA; Lai JC; Fastenberg DM; Udell IJ
Am J Ophthalmol; 2006 Nov; 142(5):721-5. PubMed ID: 16989762
[TBL] [Abstract][Full Text] [Related]
19. [Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
Hidalgo M; Reyes J; Cárdenas AM; Díaz L; Rincón S; Vanegas N; Díaz PL; Castañeda E; Arias CA
Biomedica; 2008 Jun; 28(2):284-94. PubMed ID: 18719726
[TBL] [Abstract][Full Text] [Related]
20. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
Schlech BA; Alfonso E
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S7-15. PubMed ID: 16257313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
